News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Teva Pharmaceutical Industries Limited Announces Launch of Generic Prometrium® Capsules in the United States
March 2, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories’ Prometrium® Capsules.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Europe
MORE ON THIS TOPIC
Collaboration
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
March 5, 2026
·
1 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals
March 4, 2026
·
2 min read
·
Tristan Manalac
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
